Armata Pharmaceuticals (ARMP) Common Equity (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Common Equity data on file, last reported at -$311.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 479.34% year-over-year to -$311.6 million; the trailing twelve-month figure through Mar 2026 stood at -$311.6 million (down 479.34% YoY), and the FY2025 full-year result was -$218.6 million, down 355.23% from the prior year.
• Common Equity fell to -$311.6 million in Q1 2026, from -$218.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $61.5 million in Q1 2022 to a low of -$311.6 million in Q1 2026.
• A 5-year average of -$44.5 million and a median of -$46.1 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 91.86% in 2022 and slumped 479.34% in 2026, its largest moves.
• Tracing ARMP's Common Equity over 5 years: stood at $36.1 million in 2022, then tumbled by 188.87% to -$32.1 million in 2023, then slumped by 49.76% to -$48.0 million in 2024, then tumbled by 355.23% to -$218.6 million in 2025, then tumbled by 42.54% to -$311.6 million in 2026.
• Business Quant data shows ARMP's Common Equity at -$311.6 million in Q1 2026, -$218.6 million in Q4 2025, and -$95.6 million in Q3 2025.